Key Points Moderna surged 177% after promising results from one of its cancer-related mRNA clinical trials. Analysts remain largely on the fence, with two analysts downgrading the stock to the equivalent of "sell" in recent weeks. With Moderna likely surging too far, too fast, all while it continues to dilute shareholders via convertible debt issues, you may want to be more bearish. 10 stocks we like better than Moderna › Moderna (NASDAQ: MRNA) has remained one of the market's hottest biotech stocks.
Mostramos publicamente o ponto principal. Crie uma conta gratuita para continuar lendo o artigo completo, salva-lo, comenta-lo e conecta-lo ao contexto de mercado e OSINT.